mantle cell lymphoma

From Aaushi
Jump to navigation Jump to search

Introduction

An intermediate grade lymphoma.

Classification

  • working formulation category: diffuse small cleaved cell lymphoma
  • Kiel classification: centrocytic lymphoma
  • revised European-American classification: mantle cell lymphoma

Epidemiology

Pathology

Microscopic pathology

Immunophenotype

Genetics

* also known as CCND1/cyclin D1/PRAD1

Clinical manifestations

* B symptoms: weight loss, fever, night sweats.

Laboratory

Radiology

Differential diagnosis

Management

More general terms

Additional terms

References

  1. Chan JK, Banks PM, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Harris NL, Isaacson PG, et al. A revised European-American classification of lymphoid neoplasms proposed by the International Lymphoma Study Group. A summary version. Am J Clin Pathol. 1995 May;103(5):543-60. PMID: https://www.ncbi.nlm.nih.gov/pubmed/7741099
  2. Williams Hematology, 5th ed, Beutler et al (eds), McGraw Hill, NY, 1995, pg 1054, 1080, 1085
  3. http://pathhsw5m54.ucsf.edu/case11/mcl.html
  4. mantlecell@ucsd.edu
  5. Dalla-Favera & Gaidano, Lymphomas, In: Cancer, Principles & Practice of Oncology, 6th edition, DeVita et al (eds), Lippincott & Williams, Philadelpha, 2001, pg 2220
  6. 6.0 6.1 Weisenberger: Mantle cell lymphoma, In: Neoplastic Hematopathology, Knowles DM (ed), Williams & Wilkins, Baltimore, 1992, pg 617
  7. Yatabe Y, Suzuki R, Tobinai K, Matsuno Y, Ichinohasama R, Okamoto M, Yamaguchi M, Tamaru J, Uike N, Hashimoto Y, Morishima Y, Suchi T, Seto M, Nakamura S. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood. 2000 Apr 1;95(7):2253-61. PMID: https://www.ncbi.nlm.nih.gov/pubmed/10733493
  8. Miranda RN, Briggs RC, Kinney MC, Veno PA, Hammer RD, Cousar JB. Immunohistochemical detection of cyclin D1 using optimized conditions is highly specific for mantle cell lymphoma and hairy cell leukemia. Mod Pathol. 2000 Dec;13(12):1308-14. PMID: https://www.ncbi.nlm.nih.gov/pubmed/11144927
  9. Aguilera NS, Bijwaard KE, Duncan B, Krafft AE, Chu WS, Abbondanzo SL, Lichy JH, Taubenberger JK. Differential expression of cyclin D1 in mantle cell lymphoma and other non-Hodgkin's lymphomas. Am J Pathol. 1998 Dec;153(6):1969-76. PMID: https://www.ncbi.nlm.nih.gov/pubmed/9846986
  10. 10.0 10.1 10.2 10.3 10.4 10.5 Medical Knowledge Self Assessment Program (MKSAP) 15, 16, 17, 18. American College of Physicians, Philadelphia 2009, 2012, 2015, 2018.
  11. 11.0 11.1 Rummel MJ, Niederle N, Maschmeyer G et al Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle- cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013 Apr 6;381(9873):1203-10 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23433739
  12. Hoster E, Dreyling M, Klapper W et al A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008 Jan 15;111(2):558-65. Epub 2007 Oct 25 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17962512
  13. 13.0 13.1 Tam CS, Anderson MA, Pott C et al Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. N Engl J Med 2018; 378:1211-1223. March 29, 2018 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29590547 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1715519
  14. 14.0 14.1 Otto MA FDA Approves Tablet Formulation of Acalabrutinib (Calquence) for CLL, SLL, and MCL. Medscape. Aug 5, 2022 https://www.medscape.com/viewarticle/978732
  15. 15.0 15.1 15.2 Ingram I Ibrutinib Makes Its Case for First-Line Treatment in Mantle Cell Lymphoma. Standard-of-care autologous transplant fails to prove superior to BTK inhibitor alone. MedPage Today December 11, 2022 https://www.medpagetoday.com/meetingcoverage/ashhematology/102185
  16. 16.0 16.1 16.2 Hoster E et al. Predictive value of minimal residual disease for efficacy of rituximab maintenance in mantle cell lymphoma: Results from the European Mantle Cell Lymphoma Elderly Trial. J Clin Oncol 2023 Nov 22; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37992261 https://ascopubs.org/doi/10.1200/JCO.23.00899

Patient information

mantle cell lymphoma patient information